SynthesisCirculation2019
Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality.
Synthesis in Circulation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 14 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 14 syntheses or guidelines pooled it, 319 citations in OpenAlex.
- Sex Differences in Omega-3 and Omega-6 PUFA Status: A Systematic Review and Meta-analysis of Cross-Sectional Comparisons.Advances in nutrition (Bethesda, Md.) · 2026Pooled it
- Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk.Pharmacology research & perspectives · 2026Pooled it
- Dried Blood Spots to Assess Cardiovascular-Kidney-Metabolic Health.Journal of the American Heart Association · 2025Pooled it
- Dietary and circulating omega-6 fatty acids and their impact on cardiovascular disease, cancer risk, and mortality: a global meta-analysis of 150 cohorts and meta-regression.Journal of translational medicine · 2025Pooled it
- Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis.European journal of preventive cardiology · 2025Pooled it
- Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review.The British journal of nutrition · 2024Pooled it
- Application of causal inference methods in individual-participant data meta-analyses in medicine: addressing data handling and reporting gaps with new proposed reporting guidelines.BMC medical research methodology · 2024Pooled it
- Association of omega 3 polyunsaturated fatty acids with incident chronic kidney disease: pooled analysis of 19 cohorts.BMJ (Clinical research ed.) · 2023Pooled it
- Trans Fatty Acid Biomarkers and Incident Type 2 Diabetes: Pooled Analysis of 12 Prospective Cohort Studies in the Fatty Acids and Outcomes Research Consortium (FORCE).Diabetes care · 2022Pooled it
- PUFA ω-3 and ω-6 biomarkers and sleep: a pooled analysis of cohort studies on behalf of the Fatty Acids and Outcomes Research Consortium (FORCE).The American journal of clinical nutrition · 2022Pooled it
- Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021.Arquivos brasileiros de cardiologia · 2021Guideline
- Biomarkers of dairy fat intake, incident cardiovascular disease, and all-cause mortality: A cohort study, systematic review, and meta-analysis.PLoS medicine · 2021Pooled it
- Dietary intake and biomarkers of linoleic acid and mortality: systematic review and meta-analysis of prospective cohort studies.The American journal of clinical nutrition · 2020Pooled it
- Omega-3 PUFA intake and the risk of digestive system cancers: A meta-analysis of observational studies.Medicine · 2020Pooled it
- Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16-Week, Double-Masked, Randomized Controlled Trial.Diabetes, obesity & metabolism · 2026Trial
- Trial
- Feasibility Study of Soybean Oil-Fortified Foods to Alter Blood Content of Linoleic Acid and Body Weight: A Randomized Double-Masked Placebo-Controlled Crossover Trial.The Journal of nutrition · 2026Trial
- Trial
- Effect of Beetroot Extract Supplementation on Serum Fatty Acid Profiles and Oxidative Stress Markers in Chronic Coronary Artery Disease Patients: A Secondary Analysis of a Randomized Controlled Trial.BioMed research international · 2025Trial
- The FADS1 rs174550 Genotype Modifies the n-3 and n-6 PUFA and Lipid Mediator Responses to a High Alpha-Linolenic Acid and High Linoleic Acid Diets.Molecular nutrition & food research · 2022Trial
120 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
88 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundGlobal dietary recommendations for and cardiovascular effects of linoleic acid, the major dietary omega-6 fatty acid, and its major metabolite, arachidonic acid, remain controversial. To address this uncertainty and inform international recommendations, we evaluated how in vivo circulating and tissue levels of linoleic acid (LA) and arachidonic acid (AA) relate to incident cardiovascular disease (CVD) across multiple international studies.
methodsWe performed harmonized, de novo, individual-level analyses in a global consortium of 30 prospective observational studies from 13 countries. Multivariable-adjusted associations of circulating and adipose tissue LA and AA biomarkers with incident total CVD and subtypes (coronary heart disease, ischemic stroke, cardiovascular mortality) were investigated according to a prespecified analytic plan. Levels of LA and AA, measured as the percentage of total fatty acids, were evaluated linearly according to their interquintile range (ie, the range between the midpoint of the first and fifth quintiles), and categorically by quintiles. Study-specific results were pooled using inverse-variance-weighted meta-analysis. Heterogeneity was explored by age, sex, race, diabetes mellitus, statin use, aspirin use, omega-3 levels, and fatty acid desaturase 1 genotype (when available).
resultsIn 30 prospective studies with medians of follow-up ranging 2.5 to 31.9 years, 15 198 incident cardiovascular events occurred among 68 659 participants. Higher levels of LA were significantly associated with lower risks of total CVD, cardiovascular mortality, and ischemic stroke, with hazard ratios per interquintile range of 0.93 (95% CI, 0.88-0.99), 0.78 (0.70-0.85), and 0.88 (0.79-0.98), respectively, and nonsignificantly with lower coronary heart disease risk (0.94; 0.88-1.00). Relationships were similar for LA evaluated across quintiles. AA levels were not associated with higher risk of cardiovascular outcomes; in a comparison of extreme quintiles, higher levels were associated with lower risk of total CVD (0.92; 0.86-0.99). No consistent heterogeneity by population subgroups was identified in the observed relationships.
conclusionsIn pooled global analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major cardiovascular events. These results support a favorable role for LA in CVD prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.